---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018858"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:36.121603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026

## Summary
- Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
- 2026 net revenue guidance for WAKIX: $1.0-1.04B, targeting blockbuster status.
- FDA approved pediatric cataplexy indication for WAKIX on Feb 13; commercial launch underway.
- Settled with 3 additional generic filers, now 6 of 7; generics entry no earlier than March 2030 if pediatric exclusivity granted.
- Pitolisant GR NDA submission on track for Q2 2026; orexin-2 agonist Phase 1 data expected mid-2026.

## SEC filing metadata
- accession: 0001104659-26-018858
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/0001104659-26-018858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018858
- JSON: https://secwatch.observer/filing/0001104659-26-018858.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.